CRISPR and precision medicine
Genetics plays a pivotal role in the complex web of human diseases. research has identified specific genetic variants associated with conditions such as sickle cell disease, beta-thalassemia, and certain hereditary cancers. This knowledge has led to the concept of repairing or eliminating harmful genetic mutations. By addressing the root cause, which in many cases is a specific mutation triggering a condition, we hold the potential to substantially reduce the risk of its development. Genome editing technologies address this by enabling direct modification of the causal variant.
Genome editing modifies genomic DNA to change the genetic information artificially, through both gain-of-function (e.g., gene knockin, gene activation) and loss-of-function (e.g., gene knockout) mutations. Gene therapy uses both genetic testing and genome editing to offer personalized treatments. The process begins with a thorough examination of a patient's genetic makeup to identify specific mutations that could benefit from intervention. Then, gene editing technology is used to finely tune gene expression, ultimately shaping the desired genotype.
CRISPR and Cas systems are some of the latest gene editing tools. CRISPR sequences were first reported in 1987 by Japanese researchers, and it took roughly two decades before their role in bacterial immunity was clarified (NSF; PubMed). In nature, the system allows prokaryotes, such as archaea and bacteria, to identify, process, and retain fragments of viral DNA. This capability played a crucial role in developing immune response mechanisms in these organisms. However, it has now evolved to be able to edit genes in mammals; a DNA strand can be specifically cut in vitro for therapeutic purposes. While there are several different types of CRISPR technologies, CRISPR-Cas9 is one of the most commonly used genome editing techniques due to its ease of use, versatility, and precision.
How CRISPR-Cas9 works
CRISPR-Cas9 is currently being used by geneticists and medical researchers to edit parts of the genome by removing, adding or altering sections of the DNA sequence. Jennifer Doudna and Emmanuelle Charpentier’s foundational work on CRISPR-Cas9 was recognized with the 2020 Nobel Prize in Chemistry (NSF).
The CRISPR-Cas9 system relies on two vital components:
- Cas9: Acts as "molecular scissors" to precisely cut DNA at a specified location.
- Guide RNA (gRNA): A pre-designed RNA sequence that binds to a specific DNA target, directing the Cas9 enzyme to the correct genomic location.
Once Cas9 is guided to the precise location by the guide RNA, it makes a cut across both strands of the DNA. The cell then recognizes the break and initiates DNA repair. In therapeutic design, that repair process can be leveraged to produce different edit outcomes (YourGenome; CRISPR Therapeutics):
- Disruption: Disables a target gene by introducing small insertions or deletions during repair.
- Deletion: Removes a defined stretch of DNA to eliminate a pathogenic segment or regulatory element.
- Correction/insertion: Replaces or adds a specific sequence to correct a disease-causing variant when a repair template is provided.
CRISPR in targeted therapies
CRISPR has already moved from clinical trials to regulatory approval in inherited blood disorders such as sickle cell disease and transfusion-dependent beta-thalassemia (NSF), and it continues to be explored in areas such as cancer. Cancer is influenced by both genetic and epigenetic factors and current treatments often fall short because of its complex nature. However, in combination with next-generation sequencing (NGS), CRISPR shows promise in expediting the identification, validation, and targeting of key elements involved in the disease. This approach can potentially lead to more effective and precise cancer therapies, addressing the heterogeneity of cancer by tailoring treatments to each patient's genetics.
In addition, CRISPR is also being used to identify new drug targets and biomarkers and help us to further understand drug resistance mechanisms. In therapeutic development, CRISPR is typically applied in two ways: directly editing cells to address an underlying genetic disease, and engineering cell therapies (for example, modifying immune cells) to enhance function. These programs can be delivered via ex vivo editing, where cells are edited outside the body and reinfused, or in vivo editing, where editing components are delivered directly to tissues (CRISPR Therapeutics). There are many potential benefits of using CRISPR-based treatments, including:
- Increased effectiveness: By targeting the specific genetic variant driving a disease, CRISPR may reduce reliance on systemic treatments that affect healthy tissue. Whether this translates to improved clinical outcomes depends on delivery accuracy and patient-specific factors.
- Reduced side effects: Traditional treatments can cause significant side effects due to their broad impact on the body. In contrast, CRISPR's precision allows for treatments that focus solely on the problem, minimizing collateral damage and unwanted adverse effects.
CRISPR supports the development of treatments that target specific disease-causing mutations, which may reduce the need for broader interventions and limit off-target biological effects in conditions where the causal variant is well characterized. However, there are some challenges and ethical issues to consider.
Challenges in CRISPR-based precision medicine
- Off-target effects: One of the foremost concerns is off-target effects, where CRISPR may inadvertently edit genes other than the intended target, posing risks to patient safety.
- Delivery mechanisms: Efficiently delivering the CRISPR components to the target cells is another significant hurdle. The in vivo delivery of the CRISPR system remains a challenge, as it requires the safe and precise transport of these gene-editing tools to the desired location within the body.
- Unintended mutations: The repair process following a DNA cut can sometimes introduce new, unforeseen genetic changes, emphasizing the need for meticulous oversight and rigorous safety protocols.
- Ethical considerations: The long-term effects of gene editing on human health and the potential ethical implications are subjects of intense debate. Most current therapeutic applications focus on somatic cells, which do not affect inherited DNA, while germline editing has not been approved for clinical use. Modifying the human genome raises profound questions about the consequences of such alterations for future generations.
Regulatory landscape for CRISPR-based therapies
While ethical considerations and evolving regulatory guidance on gene-editing technologies have slowed clinical uptake overall, recent approvals have established a clear clinical precedent. Exagamglogene autotemcel ("exa-cel"), marketed as Casgevy, has received authorization for sickle cell disease and transfusion-dependent beta-thalassemia from the MHRA, FDA, and European regulators (NSF; context).
Reimbursement complexity adds a downstream constraint that sponsors of CRISPR-based therapies must account for earlier in program planning. In Europe particularly, the need to negotiate pricing and payment frameworks separately across individual markets means that approval alone does not guarantee patient access — a factor that affects how sponsors assess commercial viability, site selection, and the geographic scope of their late-phase trials. In Europe, the approval process is further complicated because pricing and payment agreements must be negotiated separately with individual countries and regions, potentially hindering patient access to necessary therapies. Additionally, ongoing discussions revolve around defining and categorising genome-editing products, particularly when they are administered using different methods.
Conclusion
CRISPR-associated systems and other gene-editing tools are in active clinical development for hereditary diseases, viral infections, and certain cancers. Regulatory filings and early clinical data indicate growing, though still conditional, confidence in their therapeutic potential. Translating CRISPR-based therapies into clinical practice will require harmonized regulatory standards, rigorous safety frameworks, and clear guidance on product classification and reimbursement pathways, with responsibility, transparency, and ethical consideration at every step.
Key technical barriers remain, including editing efficiency, delivery to target cells, and reducing off-target effects. Progress on each is necessary before broad clinical deployment becomes viable. And, at the same time, it is crucial to establish a harmonized regulatory framework, both on an international and domestic level, to ensure that individuals who stand to benefit from these treatments can readily access them.